{"id":745648,"date":"2018-10-21T09:30:00","date_gmt":"2018-10-21T09:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\/"},"modified":"2025-11-07T01:26:58","modified_gmt":"2025-11-07T06:26:58","slug":"solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\/","title":{"rendered":"SOLO-1 Phase 3 Trial Demonstrates LYNPARZA\u00ae (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer"},"content":{"rendered":"<p class=\"bwalignc\">       60 Percent of Patients Receiving LYNPARZA Remained Progression-Free        at Three Years Compared to 27 Percent on Placebo Following        Platinum-Based Chemotherapy     <\/p>\n<p class=\"bwalignc\">       LYNPARZA Is the Only PARP Inhibitor to Demonstrate an Improvement in        Progression-Free Survival in First-Line Maintenance Treatment for        Newly-Diagnosed, Advanced Ovarian Cancer     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States<br \/>\n      and Canada, today announced detailed results from the Phase 3 SOLO-1<br \/>\n      trial testing LYNPARZA 300 mg tablets twice daily as a maintenance<br \/>\n      treatment for patients with newly-diagnosed advanced <i>BRCA<\/i>-mutated<br \/>\n      (<i>BRCA<\/i>m) ovarian cancer who were in complete or partial response<br \/>\n      following first-line standard platinum-based chemotherapy.\n    <\/p>\n<p>\n      Results of the trial confirm the statistically-significant and<br \/>\n      clinically-meaningful improvement in progression-free survival (PFS) for<br \/>\n      LYNPARZA as compared to placebo, reducing the risk of disease<br \/>\n      progression or death by 70 percent (HR=0.30 [95% CI, 0.23-0.41];<br \/>\n      p&lt;0.001). At 41 months of follow-up, the median PFS for patients treated<br \/>\n      with LYNPARZA was not reached compared to 13.8 months for patients<br \/>\n      treated with placebo. Of those receiving LYNPARZA, 60.4 percent remained<br \/>\n      progression-free at 36 months, compared to 26.9 percent of women in the<br \/>\n      placebo arm. The data were presented at the Presidential Symposium of<br \/>\n      the ESMO 2018 Congress in Munich, Germany and published simultaneously<br \/>\n      online in the <i>New England Journal of Medicine<\/i> (NEJM).\n    <\/p>\n<p>\n      <b>Summary of PFS as Assessed by Investigators<\/b><br \/>\n<sup><br \/>\n<b>1,2<\/b><br \/>\n<\/sup>\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n          <i>LYNPARZA<\/i><\/p>\n<p class=\"bwcellpmargin\">\n            (n=260)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n          Placebo (n=131)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwsinglebottom\">\n          Number of patients with event (%)<sup>3<\/sup>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          102 (39.2)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          96 (73.3)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwsinglebottom\">\n          Median (in months)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n          Not reached\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          13.8\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Hazard ratio (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"5\">\n          0.30 (0.23-0.41)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwsinglebottom\">\n          P-value\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"5\">\n          p&lt;0.001\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignl\">\n          <sup>1<\/sup>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Investigator-assessed\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignl\">\n          <sup>2<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Median (interquartile range) duration of follow-up 40.7 months<br \/>\n          (34.9\u201342.9) for LYNPARZA and 41.2 months (32.2\u201341.6) for placebo\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignl\">\n          <sup>3<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          Analysis was done at 50.6 percent maturity\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      Sean Bohen, executive vice president, Global Medicines Development and<br \/>\n      chief medical officer at AstraZeneca, said, \u201cThere is currently a<br \/>\n      significant unmet need in the treatment of advanced ovarian cancer<br \/>\n      because 70 percent of women relapse within the first three years after<br \/>\n      their initial treatment. The remarkable results of the SOLO-1 trial,<br \/>\n      which showed that 60 percent of women with newly-diagnosed, advanced <i>BRCA-<\/i>mutated<br \/>\n      ovarian cancer remained progression-free at three years, highlight the<br \/>\n      potential of LYNPARZA as a first-line maintenance therapy in this<br \/>\n      setting.\u201d\n    <\/p>\n<p>\n      Dr. Roy Baynes, senior vice president and head of Global Clinical<br \/>\n      Development, chief medical officer, Merck Research Laboratories, said,<br \/>\n      \u201cOur collective goal in oncology research is to improve long-term<br \/>\n      outcomes for people living with cancer. Based on the SOLO-1 trial<br \/>\n      results, LYNPARZA is the only PARP inhibitor to have demonstrated a<br \/>\n      significant and clinically-meaningful improvement in reducing the risk<br \/>\n      of progression or death for newly-diagnosed patients with advanced <i>BRCA-<\/i>mutated<br \/>\n      ovarian cancer following platinum-based chemotherapy. We are working<br \/>\n      with regulatory authorities as quickly as possible to seek approval of<br \/>\n      LYNPARZA for these patients.\u201d\n    <\/p>\n<p>\n      Kathleen Moore, co-principal investigator of the SOLO-1 trial and<br \/>\n      associate director, Stephenson Cancer Center at The University of<br \/>\n      Oklahoma, Oklahoma City, Oklahoma, said, \u201cWomen with ovarian cancer are<br \/>\n      often diagnosed with advanced disease, which unfortunately is associated<br \/>\n      with poor long-term survival rates. The newly-diagnosed setting is our<br \/>\n      best opportunity to achieve a sustained remission, since once a<br \/>\n      patient\u2019s ovarian cancer recurs, it is typically incurable. The SOLO-1<br \/>\n      results demonstrate the potential of LYNPARZA maintenance therapy<br \/>\n      earlier in the treatment pathway and reinforce the importance of<br \/>\n      identifying a patient\u2019s <i>BRCA<\/i> mutation status at the time of<br \/>\n      diagnosis \u2013 these results could change the way we treat women with<br \/>\n      advanced <i>BRCA<\/i>-mutated ovarian cancer.\u201d\n    <\/p>\n<p>\n      The SOLO-1 safety profile was in line with that observed in prior<br \/>\n      clinical trials. The most common adverse events (AEs) \u2265 20 percent were<br \/>\n      nausea (77%), fatigue (64%), vomiting (40%), anemia (39%) and diarrhea<br \/>\n      (34%). The most common \u2265 Grade 3 AEs were anemia (22%) and neutropenia<br \/>\n      (8%). Seventy-one percent of patients on LYNPARZA remained on the<br \/>\n      recommended starting dose. Additionally, 88 percent of patients on<br \/>\n      LYNPARZA continued treatment without an AE-related discontinuation.<br \/>\n      Further, 48 percent of patients on LYNPARZA did not have a dose<br \/>\n      interruption as a result of an AE.\n    <\/p>\n<p>\n      Per SOLO-1 protocol guidelines, patients who demonstrated a complete<br \/>\n      response (no radiological evidence of disease) at two years stopped<br \/>\n      treatment with LYNPARZA; patients who demonstrated a partial response<br \/>\n      and, who in the opinion of the treating physician can derive further<br \/>\n      benefit from continuous treatment, were treated beyond two years.\n    <\/p>\n<p>\n      AstraZeneca and Merck are exploring additional trials in ovarian cancer,<br \/>\n      including the ongoing GINECO\/ENGOTov25 Phase 3 trial, PAOLA-1. This<br \/>\n      trial is testing the effect of LYNPARZA<i> <\/i>in combination with<br \/>\n      bevacizumab as a maintenance treatment for patients with newly-diagnosed<br \/>\n      advanced ovarian cancer regardless of their <i>BRCA <\/i>status. Results<br \/>\n      are expected during the second half of 2019.\n    <\/p>\n<p>\n      LYNPARZA is a first-in-class poly ADP-ribose polymerase (PARP) inhibitor<br \/>\n      approved in the U.S. since 2014. LYNPARZA has a broad clinical<br \/>\n      development program and AstraZeneca and Merck are working together to<br \/>\n      deliver LYNPARZA as quickly as possible to more patients across multiple<br \/>\n      cancer types.\n    <\/p>\n<p>\n      LYNPARZA is not currently FDA-approved for advanced <i>BRCA<\/i>m ovarian<br \/>\n      cancer treatment in the first-line maintenance setting. LYNPARZA is<br \/>\n      indicated for the maintenance treatment of recurrent ovarian cancer in<br \/>\n      response to platinum-based chemotherapy regardless of <i>BRCA<\/i><br \/>\n      mutation status, and for the treatment of advanced ovarian cancer<br \/>\n      patients with a germline <i>BRCA<\/i> mutation previously treated with<br \/>\n      three or more lines of chemotherapy. Physicians should select advanced<br \/>\n      ovarian cancer patients for therapy based on a FDA-approved companion<br \/>\n      diagnostic. Please see complete indications below.\n    <\/p>\n<p>\n      <b>Important Safety Information<\/b>\n    <\/p>\n<p>\n      <b>Contraindications<\/b>\n    <\/p>\n<p>\n      There are no contraindications for LYNPARZA.\n    <\/p>\n<p>\n      <b>Warnings and Precautions<\/b>\n    <\/p>\n<p>\n      <b>Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML)<\/b>:<br \/>\n      Occurred in &lt;1.5% of patients exposed to LYNPARZA monotherapy, and the<br \/>\n      majority of events had a fatal outcome. The duration of therapy in<br \/>\n      patients who developed secondary MDS\/AML varied from &lt;6 months to &gt;2<br \/>\n      years. All of these patients had previous chemotherapy with platinum<br \/>\n      agents and\/or other DNA-damaging agents, including radiotherapy, and<br \/>\n      some also had a history of more than one primary malignancy or of bone<br \/>\n      marrow dysplasia.\n    <\/p>\n<p>\n      Do not start LYNPARZA until patients have recovered from hematological<br \/>\n      toxicity caused by previous chemotherapy (\u2264Grade 1). Monitor complete<br \/>\n      blood count for cytopenia at baseline and monthly thereafter for<br \/>\n      clinically significant changes during treatment. For prolonged<br \/>\n      hematological toxicities, interrupt LYNPARZA and monitor blood count<br \/>\n      weekly until recovery.\n    <\/p>\n<p>\n      If the levels have not recovered to Grade 1 or less after 4 weeks, refer<br \/>\n      the patient to a hematologist for further investigations, including bone<br \/>\n      marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA<br \/>\n      if MDS\/AML is confirmed.\n    <\/p>\n<p>\n      <b>Pneumonitis<\/b>: Occurred in &lt;1% of patients exposed to LYNPARZA, and<br \/>\n      some cases were fatal. If patients present with new or worsening<br \/>\n      respiratory symptoms such as dyspnea, cough, and fever, or a<br \/>\n      radiological abnormality occurs, interrupt LYNPARZA treatment and<br \/>\n      initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is<br \/>\n      confirmed and treat patient appropriately.\n    <\/p>\n<p>\n      <b>Embryo-Fetal Toxicity:<\/b> Based on its mechanism of action and<br \/>\n      findings in animals,\n    <\/p>\n<p>\n      LYNPARZA can cause fetal harm. A pregnancy test is recommended for<br \/>\n      females of\n    <\/p>\n<p>\n      reproductive potential prior to initiating treatment.\n    <\/p>\n<p>\n      <i>Females<\/i>\n    <\/p>\n<p>\n      Advise females of reproductive potential of the potential risk to a<br \/>\n      fetus and to use effective contraception during treatment and for 6<br \/>\n      months following the last dose.\n    <\/p>\n<p>\n      <i>Males<\/i>\n    <\/p>\n<p>\n      Advise male patients with female partners of reproductive potential or<br \/>\n      who are pregnant to use effective contraception during treatment and for<br \/>\n      3 months following the last dose of LYNPARZA and to not donate sperm<br \/>\n      during this time.\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014Maintenance Setting<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA in the maintenance setting for SOLO-2:<br \/>\n      nausea (76%), fatigue (including asthenia) (66%), anemia (44%), vomiting<br \/>\n      (37%), nasopharyngitis\/upper respiratory tract infection (URI)\/influenza<br \/>\n      (36%), diarrhea (33%), arthralgia\/myalgia (30%), dysgeusia (27%),<br \/>\n      headache (26%), decreased appetite (22%), and stomatitis (20%).\n    <\/p>\n<p>\n      Study 19: nausea (71%), fatigue (including asthenia) (63%), vomiting<br \/>\n      (35%), diarrhea (28%), anemia (23%), respiratory tract infection (22%),<br \/>\n      constipation (22%), headache (21%), and decreased appetite (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the maintenance setting (SOLO-2\/Study 19)<br \/>\n      were: increase in mean corpuscular volume (89%\/82%), decrease in<br \/>\n      hemoglobin (83%\/82%), decrease in leukocytes (69%\/58%), decrease in<br \/>\n      lymphocytes (67%\/52%), decrease in absolute neutrophil count (51%\/47%),<br \/>\n      increase in serum creatinine (44%\/45%), and decrease in platelets<br \/>\n      (42%\/36%).\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014Advanced g<i>BRCA<\/i>m Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA for advanced g<i>BRCA<\/i>m ovarian cancer<br \/>\n      after 3 or more lines of chemotherapy (pooled from 6 studies) were:<br \/>\n      fatigue (including asthenia) (66%), nausea (64%), vomiting (43%), anemia<br \/>\n      (34%), diarrhea (31%), nasopharyngitis\/upper respiratory tract infection<br \/>\n      (URI) (26%), dyspepsia (25%), myalgia (22%), decreased appetite (22%),<br \/>\n      and arthralgia\/musculoskeletal pain (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA for advanced g<i>BRCA<\/i>m ovarian cancer<br \/>\n      (pooled from 6 studies) were: decrease in hemoglobin (90%), increase in<br \/>\n      mean corpuscular volume (57%), decrease in lymphocytes (56%), increase<br \/>\n      in serum creatinine (30%), decrease in platelets (30%), and decrease in<br \/>\n      absolute neutrophil count (25%).\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014g<i>BRCA<\/i>m, HER2-Negative Breast Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      OlympiAD were: nausea (58%), anemia (40%), fatigue (including asthenia)<br \/>\n      (37%), vomiting (30%), neutropenia (27%), respiratory tract infection<br \/>\n      (27%), leukopenia (25%), diarrhea (21%), and headache (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in &gt;25% of patients in<br \/>\n      OlympiAD were: decrease in hemoglobin (82%), decrease in lymphocytes<br \/>\n      (73%), decrease in leukocytes (71%), increase in mean corpuscular volume<br \/>\n      (71%), decrease in absolute neutrophil count (46%), and decrease in<br \/>\n      platelets (33%).\n    <\/p>\n<p>\n      <b>Drug Interactions<\/b>\n    <\/p>\n<p>\n      <b>Anticancer Agents: <\/b>Clinical studies of LYNPARZA in combination<br \/>\n      with other myelosuppressive anticancer agents, including DNA-damaging<br \/>\n      agents, indicate a potentiation and prolongation of myelosuppressive<br \/>\n      toxicity.\n    <\/p>\n<p>\n      <b>CYP3A Inhibitors: <\/b>Avoid concomitant use of strong or moderate<br \/>\n      CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must be<br \/>\n      co-administered, reduce the dose of LYNPARZA. Advise patients to avoid<br \/>\n      grapefruit, grapefruit juice, Seville oranges, and Seville orange juice<br \/>\n      during LYNPARZA treatment.\n    <\/p>\n<p>\n      <b>CYP3A Inducers: <\/b>Avoid concomitant use of strong or moderate CYP3A<br \/>\n      inducers when using LYNPARZA. If a moderate inducer cannot be avoided,<br \/>\n      there is a potential for decreased efficacy of LYNPARZA.\n    <\/p>\n<p>\n      <b>Use In Specific Populations<\/b>\n    <\/p>\n<p>\n      <b>Lactation: <\/b>No data are available regarding the presence of<br \/>\n      olaparib in human milk, its effects on the breastfed infant or on milk<br \/>\n      production. Because of the potential for serious adverse reactions in<br \/>\n      the breastfed infant, advise a lactating woman not to breastfeed during<br \/>\n      treatment with LYNPARZA and for 1 month after receiving the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use: <\/b>The safety and efficacy of LYNPARZA have not been<br \/>\n      established in pediatric patients.\n    <\/p>\n<p>\n      <b>Hepatic Impairment: <\/b>No adjustment to the starting dose is<br \/>\n      required in patients with mild hepatic impairment (Child-Pugh<br \/>\n      classification A). There are no data in patients with moderate or severe<br \/>\n      hepatic impairment.\n    <\/p>\n<p>\n      <b>Renal Impairment: <\/b>No adjustment to the starting dose is necessary<br \/>\n      in patients with mild renal impairment (CLcr=51-80 mL\/min). In patients<br \/>\n      with moderate renal impairment (CLcr=31-50 mL\/min), reduce the dose to<br \/>\n      200 mg twice daily. There are no data in patients with severe renal<br \/>\n      impairment or end-stage renal disease (CLcr \u226430 mL\/min).\n    <\/p>\n<p>\n      <b>Indications<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with recurrent<br \/>\n      epithelial ovarian, fallopian tube, or primary peritoneal cancer, who<br \/>\n      are in complete or partial response to platinum-based chemotherapy.\n    <\/p>\n<p>\n      For the treatment of adult patients with deleterious or suspected<br \/>\n      deleterious germline <i>BRCA-<\/i>mutated (g<i>BRCA<\/i>m) advanced<br \/>\n      ovarian cancer who have been treated with 3 or more prior lines of<br \/>\n      chemotherapy. Select patients for therapy based on an FDA-approved<br \/>\n      companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      In patients with deleterious or suspected deleterious g<i>BRCA<\/i>m,<i> <\/i>human<br \/>\n      epidermal growth factor receptor 2 (HER2)-negative metastatic breast<br \/>\n      cancer who have previously been treated with chemotherapy in the<br \/>\n      neoadjuvant, adjuvant or metastatic setting. Patients with hormone<br \/>\n      receptor (HR)-positive breast cancer should have been treated with a<br \/>\n      prior endocrine therapy or be considered inappropriate for endocrine<br \/>\n      treatment. Select patients for therapy based on an FDA-approved<br \/>\n      companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Please see complete <\/b><br \/>\n<a href=\"https:\/\/www.azpicentral.com\/lynparza_tb\/lynparza_tb.pdf\" rel=\"nofollow\"><br \/>\n<b>Prescribing<br \/>\n      Information<\/b><br \/>\n<\/a><br \/>\n<b>, including Patient Information (Medication Guide).<\/b>\n    <\/p>\n<p>\n      <b>About the SOLO-1 Phase 3 Trial<\/b>\n    <\/p>\n<p>\n      SOLO-1 is a Phase 3, randomized, double-blind, placebo-controlled,<br \/>\n      multi-center trial to evaluate the efficacy and safety of LYNPARZA<br \/>\n      tablets (300 mg<i> <\/i>twice daily) as maintenance monotherapy compared<br \/>\n      with placebo in newly-diagnosed patients with advanced <i>BRCA<\/i>-mutated<br \/>\n      ovarian cancer following platinum-based chemotherapy. The trial<br \/>\n      randomized 391 patients with a deleterious or suspected deleterious <i>BRCA1<\/i><br \/>\n      or <i>BRCA2<\/i> mutation who were in clinical complete or partial<br \/>\n      response following platinum-based chemotherapy. Patients were randomized<br \/>\n      (2:1) to receive LYNPARZA or placebo for up to two years or until<br \/>\n      disease progression (at the investigator\u2019s discretion). The primary<br \/>\n      endpoint was investigator-assessed progression-free survival and key<br \/>\n      secondary endpoints include time to second disease progression or death,<br \/>\n      time to first subsequent treatment and overall survival.\n    <\/p>\n<p>\n      <b>About Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Approximately 20,000 women in the U.S. are diagnosed with ovarian cancer<br \/>\n      (including ovarian, fallopian tube and primary peritoneal cancers) each<br \/>\n      year. Among women in the U.S., it is the ninth most common cancer and<br \/>\n      the fifth leading cause of cancer death.\n    <\/p>\n<p>\n      The risk of developing ovarian cancer is increased in women with<br \/>\n      specific inherited genetic abnormalities, including <i>BRCA<\/i><br \/>\n      mutations.\n    <\/p>\n<p>\n      <b>About <i>BRCA<\/i> Mutations<\/b>\n    <\/p>\n<p>\n      <i>BRCA<\/i>1 and <i>BRCA<\/i>2 are human genes that produce proteins<br \/>\n      responsible for repairing damaged DNA and play an important role in<br \/>\n      maintaining the genetic stability of cells. When either of these genes<br \/>\n      is mutated, or altered, such that its protein product either is not made<br \/>\n      or does not function correctly, DNA damage may not be repaired properly,<br \/>\n      and cells become unstable. As a result, cells are more likely to develop<br \/>\n      additional genetic alterations that can lead to cancer.\n    <\/p>\n<p>\n      <b>About LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (olaparib)<\/b>\n    <\/p>\n<p>\n      LYNPARZA is the first-in-class PARP inhibitor and the first targeted<br \/>\n      treatment to potentially exploit DNA damage response (DDR) pathway<br \/>\n      deficiencies, such as&nbsp;<i>BRCA<\/i>&nbsp;mutations, to preferentially kill<br \/>\n      cancer cells. Specifically, <i>in vitro<\/i> studies have shown that<br \/>\n      LYNPARZA-induced cytotoxicity may involve inhibition of PARP enzymatic<br \/>\n      activity and increased formation of PARP-DNA complexes, resulting in DNA<br \/>\n      damage and cancer cell death.<sup> <\/sup>LYNPARZA is being tested in a<br \/>\n      range of DDR-deficient tumor types.\n    <\/p>\n<p>\n      LYNPARZA, which is being jointly developed and commercialized by<br \/>\n      AstraZeneca and Merck, has a broad and advanced clinical trial<br \/>\n      development program, and AstraZeneca and Merck are working together to<br \/>\n      deliver it as quickly as possible to more patients across multiple<br \/>\n      cancer types.\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n    <\/p>\n<p>\n      In July 2017, AstraZeneca and Merck, known as MSD outside the United<br \/>\n      States and Canada, announced a global strategic oncology collaboration<br \/>\n      to co-develop and co-commercialize LYNPARZA, the world\u2019s first PARP<br \/>\n      inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for<br \/>\n      multiple cancer types. Working together, the companies will develop<br \/>\n      LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as monotherapies. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, the potential<br \/>\n      to bring new hope to people with cancer drives our purpose and<br \/>\n      supporting accessibility to our cancer medicines is our commitment.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the largest development<br \/>\n      programs in the industry across more than 30 tumor types. We also<br \/>\n      continue to strengthen our portfolio through strategic acquisitions and<br \/>\n      are prioritizing the development of several promising oncology<br \/>\n      candidates with the potential to improve the treatment of advanced<br \/>\n      cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/index.html\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/www.youtube.com\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20181021005027r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Michael        Close, 267-305-1211<br \/>or<br \/>Investors<br \/>Teri Loxam, 908-740-1986<br \/>or<br \/>Michael        DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced detailed results from the Phase 3 SOLO-1 trial testing LYNPARZA 300 mg tablets twice daily as a maintenance treatment for patients with newly-diagnosed advanced BRCA -mutated ( BRCA m) ovarian cancer who were in complete or partial response following first-line standard platinum-based chemotherapy. Results of the trial confirm the statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for LYNPARZA as compared to placebo, reducing the risk of disease progression or death by 70 percent (HR=0.30 [95% CI, 0.23-0.41]; p&lt;0.001). At 41 months of follow-up, the median PFS for patients treated with LYNPARZA was not reached compared to 13.8 months for patients treated with placebo. Of those receiving LYNPARZA, 60.4 percent remained progression-free at 36 months, compared to 26.9 percent of women in the placebo arm. The data were presented at the<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289,56],"class_list":["post-745648","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SOLO-1 Phase 3 Trial Demonstrates LYNPARZA\u00ae (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SOLO-1 Phase 3 Trial Demonstrates LYNPARZA\u00ae (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced detailed results from the Phase 3 SOLO-1 trial testing LYNPARZA 300 mg tablets twice daily as a maintenance treatment for patients with newly-diagnosed advanced BRCA -mutated ( BRCA m) ovarian cancer who were in complete or partial response following first-line standard platinum-based chemotherapy. Results of the trial confirm the statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for LYNPARZA as compared to placebo, reducing the risk of disease progression or death by 70 percent (HR=0.30 [95% CI, 0.23-0.41]; p&lt;0.001). At 41 months of follow-up, the median PFS for patients treated with LYNPARZA was not reached compared to 13.8 months for patients treated with placebo. Of those receiving LYNPARZA, 60.4 percent remained progression-free at 36 months, compared to 26.9 percent of women in the placebo arm. The data were presented at the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\\\/\",\"name\":\"SOLO-1 Phase 3 Trial Demonstrates LYNPARZA\u00ae (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-10-21T09:30:00+00:00\",\"dateModified\":\"2025-11-07T06:26:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SOLO-1 Phase 3 Trial Demonstrates LYNPARZA\u00ae (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SOLO-1 Phase 3 Trial Demonstrates LYNPARZA\u00ae (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\/","og_locale":"en_US","og_type":"article","og_title":"SOLO-1 Phase 3 Trial Demonstrates LYNPARZA\u00ae (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer - Merck.com","og_description":"AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced detailed results from the Phase 3 SOLO-1 trial testing LYNPARZA 300 mg tablets twice daily as a maintenance treatment for patients with newly-diagnosed advanced BRCA -mutated ( BRCA m) ovarian cancer who were in complete or partial response following first-line standard platinum-based chemotherapy. Results of the trial confirm the statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for LYNPARZA as compared to placebo, reducing the risk of disease progression or death by 70 percent (HR=0.30 [95% CI, 0.23-0.41]; p&lt;0.001). At 41 months of follow-up, the median PFS for patients treated with LYNPARZA was not reached compared to 13.8 months for patients treated with placebo. Of those receiving LYNPARZA, 60.4 percent remained progression-free at 36 months, compared to 26.9 percent of women in the placebo arm. The data were presented at the","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:58+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\/","name":"SOLO-1 Phase 3 Trial Demonstrates LYNPARZA\u00ae (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-10-21T09:30:00+00:00","dateModified":"2025-11-07T06:26:58+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/solo-1-phase-3-trial-demonstrates-lynparza-olaparib-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovari\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"SOLO-1 Phase 3 Trial Demonstrates LYNPARZA\u00ae (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"b5e2a5c5-ba42-4de6-8dbc-71675f97982c","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2018\/10\/1\/3575531_NEJM_KM_Curve.jpg","size":"443883","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2018\/10\/1\/merck_logo.jpg","size":"21167","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/SOLO-1-Phase-3-Trial-Demonstrates-LYNPARZA-olaparib-Maintenance-Therapy-Cut-the-Risk-of-Disease-Progression-or-Death-by-70-Percent-in-NZZVW.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745648\/revisions"}],"predecessor-version":[{"id":3674999,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745648\/revisions\/3674999"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745648"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}